5月6日 - ** 制药公司BioCryst Pharmaceuticals BCRX.O的股价在盘前交易中下跌4.8%，至8.60美元
** 该公司公布第一季度每股亏损2.98美元，而分析师平均预期为每股盈利5美分——路孚特数据
** BCRX季度营收1.564亿美元，高于分析师平均预期的1.511亿美元
** 公司维持Orladeyo年度营收预测区间在6.25亿至6.45亿美元
** Orladeyo是一种每日服用一次的药片，有助于预防遗传性血管性水肿患者（一种罕见的遗传性疾病）的肿胀发作
** 截至上一交易日收盘，该股年内累计涨幅达15.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.